{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:05:27Z","timestamp":1781787927031,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":242,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["gimopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine Open"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.gimo.2023.100832","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T02:23:13Z","timestamp":1694226193000},"page":"100832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A\u00a0therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)"],"prefix":"10.1016","volume":"1","author":[{"given":"Arthur","family":"Lenahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuntal","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gimo.2023.100832_bib1","series-title":"GeneReviews","first-page":"1993","article-title":"Friedreich ataxia","author":"Bidichandani","year":"2017"},{"issue":"1","key":"10.1016\/j.gimo.2023.100832_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.gimo.2023.100832_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s13023-022-02568-3","article-title":"Clinical management guidelines for Friedreich ataxia: best practice in rare diseases","volume":"17","author":"Corben","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gimo.2023.100832_bib4","article-title":"Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review","volume":"3","author":"Jain","year":"2022","journal-title":"Ther Adv Rare Dis"},{"issue":"4","key":"10.1016\/j.gimo.2023.100832_bib5","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.3390\/ijms14047853","article-title":"Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons","volume":"14","author":"D\u2019Oria","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.gimo.2023.100832_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1016\/j.gimo.2023.100832_bib7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/acn3.51686","article-title":"Harmonizing results of ataxia rating scales: mFARS, SARA, and ICARS","volume":"9","author":"Rummey","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.gimo.2023.100832_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.gimo.2023.100832_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe Extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.gimo.2023.100832_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14728214.2021.1998452","article-title":"Designing phase II clinical trials in Friedreich ataxia","volume":"26","author":"Rodden","year":"2021","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Genetics in Medicine Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949774423008415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949774423008415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:10:20Z","timestamp":1762650620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949774423008415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2949774423008415"],"URL":"https:\/\/doi.org\/10.1016\/j.gimo.2023.100832","relation":{},"ISSN":["2949-7744"],"issn-type":[{"value":"2949-7744","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A\u00a0therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gimo.2023.100832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"100832"}}